Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||TP53 loss|
|Therapy||Alemtuzumab + Rituximab|
|Indication/Tumor Type||chronic lymphocytic leukemia/small lymphocytic lymphoma|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 loss||chronic lymphocytic leukemia/small lymphocytic lymphoma||sensitive||Alemtuzumab + Rituximab||Guideline||Actionable||Campath (alemtuzumab) combined with Rituxan (rituximab) is indicated in the guidelines as first-line therapy and second line and subsequent therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma patients with TP53 loss (NCCN.org).||detail...|
|PubMed Id||Reference Title||Details|